Search results for " ES-SCLC"

showing 1 items of 1 documents

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cance…

2021

Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international regulatory agencies. The current work aims to assess different efficacy and safety profiles among chemoimmunotherapy plus immuno-oncology (CT+IO) approaches according to different immune checkpoint inhibitor (ICI) subtypes. Material & Methods: We included in our meta-analysis six first-line randomised controlled trials (RCTs) comparing the association of single-agent ICI with CT versus CT al…

0301 basic medicineOncologymedicine.medical_specialtyImmunotherapy for Lung Cancer: Progress Opportunities and Challengesmedicine.medical_treatmentCellFood and drug administration03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemo-immunotherapy ES-SCLC indirect comparison meta-analysis PD-L1/PD-1 inhibitorsChemo immunotherapyRC254-282ChemotherapyLungbusiness.industryPD-L1/PD-1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensIndirect comparison030104 developmental biologymedicine.anatomical_structureOncologyindirect comparison030220 oncology & carcinogenesisMeta-analysischemo-immunotherapybusinessExtensive-stage small cell lung cancerES-SCLCMeta-AnalysisTherapeutic Advances in Medical Oncology
researchProduct